Azacitidine
- Atc Codes:L01BC07
- CAS Codes:320-67-2
- PHARMGKB ID:320-67-2
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Substrate of
- Inhibits
- Induces
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Vidaza; Belgium: Vidaza; Bulgaria: Vidaza; Cyprus: Vidaza; Czech Republic: Vidaza; Denmark: Vidaza; Estonia: Vidaza; Finland: Vidaza; France: Vidaza; Germany: Vidaza; Greece: Vidaza; Hungary: Vidaza; Ireland: Vidaza; Latvia: Vidaza; Lithuania: Vidaza; Luxembourg: Vidaza; Netherlands: Vidaza; Poland: Vidaza; Portugal: Vidaza; Romania: Vidaza; Slovakia: Vidaza; Slovenia: Vidaza; Spain: Vidaza; Sweden: Vidaza; UK: Vidaza.
North America
USA: Vidaza.
Drug combinations
Chemistry
Azacitidine: C~8~H~12~N~4~O~5~. Mw: 244.20. (1) 1,3,5-Triazin-2(1H)-one, 4-amino-1-β-D-ribofuranosyl-; (2) 4-Amino-1-β-D-ribofuranosyl-s-triazin-2(1H)-one. CAS-320-67-2 (1978).
Pharmacologic Category
Antineoplastic Agents; Antimetabolites; Pyrimidine Analogs; DNA Methylation Inhibitor. (ATC-Code: L01BC07).
Mechanism of action
Promotes hypomethylation of DNA, leading to direct toxicity of abnormal hematopoietic cells in the bone marrow.
Therapeutic use
Treatment of myelodysplastic syndrome.
Pregnancy and lactiation implications
Pregnancy should be avoided during treatment. Use not recommended during lactation.
Unlabeled use
Treatment of myelogenous leukemia.
Contraindications
Hypersensitivity to azacitidine, mannitol, or any component of the formulation. Advanced malignant hepatic tumors.
Warnings and precautions
Hazardous agent. Neutropenia and thrombocytopenia are common. May be hepatotoxic. Renal toxicities (serum creatinine elevations, renal tubular acidosis, and renal failure) may occur. Use with caution in hepatic or renal impairment.